Why did Becton, Dickinson and Company (NYSE:BDX) revenue increase?

Becton, Dickinson and Company (NYSE:BDX) reported revenue growth across all four operating segments, supported by its U.S. business. Total revenue increased 5.4% to $4.98 billion, including 4.4% growth after removing currency movements.

What were Becton, Dickinson and Company’s (NYSE:BDX) Q3 earnings?

Becton, Dickinson and Company (NYSE:BDX) reported GAAP diluted EPS of $1.64 and adjusted diluted EPS of $3.23. These figures increased 4.5% and 4.9%, respectively, from the prior-year quarter.

How did Becton, Dickinson and Company’s (NYSE:BDX) segments perform?

Becton, Dickinson and Company (NYSE:BDX) reported 4.5% growth in Medical Essentials, 4.9% in Connected Care, 6.6% in BioPharma Systems and 6.4% in Interventional.

What is Becton, Dickinson and Company’s (NYSE:BDX) updated guidance?

Becton, Dickinson and Company (NYSE:BDX) now expects adjusted diluted EPS of $12.62–$12.72, compared with its previous $12.52–$12.72 range. The company maintained low single-digit revenue growth guidance but expects results toward the range’s upper end.

What does the Waters transaction mean for Becton, Dickinson and Company (NYSE:BDX)?

Becton, Dickinson and Company (NYSE:BDX) separated its former Biosciences and Diagnostic Solutions operations and combined them with Waters in February 2026. BD now reports Medical Essentials, Connected Care, BioPharma Systems and Interventional as its four continuing-operations segments.

Technology

Image for illustrative purposes only. Not a real photo.

BD delivers a massive $5B revenue quarter

Written by Mahathir BayenaPublished Aug 6, 2026, 12:07 PM

BD reported fiscal Q3 2026 revenue of $4.98 billion, up 5.4% year over year.
Adjusted diluted EPS increased 4.9% to $3.23, while GAAP diluted EPS reached $1.64.
The company raised the midpoint of its full-year adjusted EPS guidance after growth across all four segments.

BD (NYSE:BDX) reported fiscal Q3 2026 revenue of $4.98 billion, up 5.4% as reported and 4.4% currency-neutral.

Revenue increased from $4.73 billion, while adjusted diluted EPS rose 4.9% to $3.23 from $3.08.

Year-to-date operating cash flow increased 33.3% to $2.10 billion, while free cash flow rose 44.6% to $1.73 billion.

BD raised adjusted EPS guidance to $12.62–$12.72.

Following the announcement, BD's share price was up 0.3% at $170.66 in premarket trading.

All four segments grew, led by BioPharma Systems at 6.6% and Interventional at 6.4%.

Meanwhile, BD completed its Biosciences and Diagnostic Solutions spin-off and Waters combination in February, leaving four continuing-operations segments.

BD delivers a massive $5B revenue quarter

Frequently asked questions

BD delivers a massive $5B revenue quarter

Frequently asked questions

Assets related to this article